Jonathan Rosenberg
As seen in:
LinkedIn,
CNN,
Medium,
The New York Times,
Business Insider,
Forbes,
Nature,
The Washington Post,
TIME,
Yahoo News
and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Jonathan Rosenberg
BCANTT 2026: MIBC: How to Manage the Bladder after EVP
(UroToday.com) The Bladder Cancer Advocacy Network (BCAN) Bladder Cancer Think Tank 2026 was host to the EV + Pembrolizumab in Urothelial Cancer: Key Questions in a Changing Treatment Landscape Session. Dr. Vadim Koshkin and Joshua Meeks co-chaired this session. Drs. Jonathan Rosenberg, Ashish Kamat, Sima P. Porten and Jon Treffert discussed How to Manage the Bladder after EVP.
A guide to MATLAB: for beginners and experienced users
Ayuda Buscar en la ayuda Buscar en la ayuda
As Evidence Mounts for Molecular Testing-Guided Bladder Cancer Care, Should Results Override Clinical Judgement?
This transcript has been lightly edited for style and clarity. Oncology News Central (ONC): Where do things currently stand in clinic regarding the use of molecular testing to inform treatment decisions in bladder cancer? Jonathan E. Rosenberg, MD: I think we’re now moving beyond simply just testing for somatic mutations.
Coronary Intravascular Lithotripsy For Acute Stent Underexpansion: A Case Series
© 2025 HMP Global. All Rights Reserved. Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of the Journal of Invasive Cardiology or HMP Global, their employees, and affiliates. J INVASIVE CARDIOL 2025. doi:10.25270/jic/25.00293. Epub September 30, 2025.
After Years of Inactivity, “Dizzying” Changes Hit Bladder Cancer Care
This transcript has been lightly edited for style and clarity. Robert A. Figlin, MD: Hello, this is Bob Figlin, the Steven Spielberg Family Chair in Hematology-Oncology and director of Cedars-Sinai Cancer Center. I’m absolutely delighted to welcome Jonathan Rosenberg, a long-time friend, chief of the genitourinary oncology service at Memorial Sloan Kettering Cancer Center and the Enno W. Ercklentz Chair. Jonathan, good to see you. Jonathan E. Rosenberg, MD: Good to see you, as well.
Clinical Outcomes, Genomic Heterogeneity, and Therapeutic Considerations Across Histologic Subtypes of Urothelial Carcinoma
Keywords Divergent differentiation Histologic subtype Neoadjuvant chemotherapy Next-generation sequencing Urothelial carcinoma Variant histology What does this study add? Despite the high prevalence of aberrant histology in urothelial carcinoma (UC), the variability in clinical behavior, lack of consistent reporting, and absence of established prognostic biomarkers are barriers to meaningful treatment advances for patients with bladder cancer.
Enfortumab vedotin and pembrolizumab: redefining the standard of care for previously untreated advanced urothelial cancer
ABSTRACT Combination treatment with Enfortumab vedotin (EV), an antibody drug conjugate targeting Nectin-4 with a monomethyl auristatin E (MMAE) payload, and pembrolizumab, a programmed death 1 (PD-1) inhibitor, has become the new standard of care for previously untreated locally advanced or metastatic urothelial carcinoma.
Council Post: The Importance Of Contextual Data In GenAI—And Where To Find It
Pioneer in the telecommunications industry with over 25 years of experience. Jonathan Rosenberg is the CTO and Head of AI at Five9. To understand the new data requirements for B2B generative AI (GenAI) use cases—and the challenges many organizations may face in making that data available—business leaders need to understand what “contextual data” is and the types of contextual data needed for each GenAI use case.
Molecular heterogeneity in urothelial carcinoma and determinants of clinical benefit to PD-L1 blockade
|
Keywords urothelial carcinoma transcriptomics molecular heterogeneity PD-L1 blockade patient stratification digital pathology Get full text access Log in, subscribe or purchase for full access. References 1. Ishida, Y. ∙ Agata, Y. ∙ Shibahara, K. ... Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death EMBO J. 1992; 11:3887-3895 2. Tang, J. ∙ Yu, J.X. ∙ Hubbard-Lucey, V.M. ...
By Habib Hamidi, Yasin Senbabaoglu, Niha Beig, Juliette Roels, Cyrus Manuel, Xiangnan Guan, Hartmut Koeppen, Zoe June Assaf, Barzin Y. Nabet, Adrian Waddell, Kobe Yuen, Sophia Maund, Ethan S Sokol, Jennifer M. Giltnane, Amber Schedlbauer, Eloisa Fuentes, James Cowan, Edward E. Kadel, Viraj Degaonkar, Alexander Y. Andreev-Drakhlin, Patrick Williams, Corey Carter, Suyasha Gupta, Elizabeth E. Steinberg, Yohann Loriot, Joaquim Bellmunt, Petros Grivas, Jonathan Rosenberg, Matthew D. Galsky, Thomas Powles, Sanjeev Mariathasan, Romain Banchereau
|
Cell Press
Verified
Innovative Therapies in GU Cancers: Promising Targets in Urothelial and Kidney Cancer - Jonathan Rosenberg
Read the Full Video Transcript Alicia Morgans: Hi, I am so excited to be here today with Professor Jonathan Rosenberg, who is joining me from Memorial Sloan Kettering after a fantastic discussion at ESMO 2024, where he talked about some novel therapies in GU cancers. Thank you so much for joining me today, Jonathan. Why don't you take it away? Jonathan Rosenberg: It's my pleasure to be here. Today I'm going to discuss two abstracts, focusing on first bladder cancer and then urothelial cancer.
New Dual-Target Drug Shows Promise Against Bladder Cancer - Jonathan Rosenberg
Read the Full Video Transcript Alicia Morgans: Hi, I am so excited to be here today with Professor Jonathan Rosenberg, who is joining me from Memorial Sloan Kettering after a fantastic discussion at ESMO 2024, where he talked about some novel therapies in GU cancers. Thank you so much for joining me today, Jonathan. Why don't you take it away? Jonathan Rosenberg: It's my pleasure to be here. Today I'm going to discuss two abstracts, focusing on first bladder cancer and then urothelial cancer.
EV-103 Cohort A: 5-Year Survival Outcomes in Cisplatin-Ineligible Patients - Jonathan Rosenberg
Read the Full Video Transcript Alicia Morgans: Hi, I'm so excited to be here today with Professor Jonathan Rosenberg, who is joining me from Memorial Sloan Kettering after a wonderful presentation at ESMO 2024, where he gave us an update on EV-103 Cohort A and some five-year outcomes. Thank you so much for being here, and please take it away. Jonathan Rosenberg: Thank you so much, Alicia. It's great to be here to talk and update people about the five-year outcomes.
Council Post: 9 Things All Enterprises Should Be Asking Of Their SaaS Vendors
Pioneer in the telecommunications industry with over 25 years of experience. Jonathan Rosenberg is the CTO and Head of AI at Five9. I work as CTO and head of AI at Five9. We serve some of the largest enterprises in the world, and over the past few years, we’ve seen an evolution in the types of capabilities these customers are asking of us—many of which apply to any B2B software-as-a-service (SaaS) offering, not just contact-center-as-a-service (CCaaS) solutions.
Council Post: Four Safe Applications Of Generative AI In The Contact Center
Pioneer in the telecommunications industry with over 25 years of experience. Jonathan Rosenberg is currently the CTO and Head of AI at Five9 When generative AI (GenAI) burst onto the scene with the arrival of ChatGPT, it became immediately apparent that this technology would have immense applications in the contact center. After all, ChatGPT was the best chatbot the world had ever seen.
EV-302 Subgroup Analyses: Enfortumab Vedotin + Pembrolizumab Effective Across Patient Subsets in Metastatic Urothelial Cancer - Jonathan Rosenberg
Read the Full Video Transcript Alicia Morgans: Hi, I'm so excited to be here today with Dr. Jonathan Rosenberg, who is a professor and the Chief of the GU Oncology service at Memorial Sloan Kettering Cancer Center. Thank you so much for being here with me today. Jonathan Rosenberg: It's my pleasure. Thank you so much for having me. Alicia Morgans: Wonderful.
Lighting the torch: intratumoural T cell-to-stroma enrichment score as a predictor of immunotherapy response in urothelial carcinoma - Nature Reviews Clinical Oncology
T cell infiltration in the tumour microenvironment (TME) is a prerequisite for sustained antitumour immune responses. However, identifying predictive biomarkers that quantify T cell infiltration and the presence of proinflammatory TMEs associated with immune-checkpoint inhibitor (ICI) response for clinical implementation has proved challenging.
Contextual Data: The New Gold in the Era of Generative AI
Undoubtedly, AI has undergone a series of dramatic breakthroughs in the past few years. Underneath all of those breakthroughs has been one core truth – more data means better results. As an enterprise wanting to deploy AI-based applications like voice bots, chatbots, or agent assistants, this meant collecting lots of data to be used for training purposes.
Health-related Quality of Life in Patients with Previously Treated Advanced Urothelial Carcinoma from EV-301: A Phase 3 Trial of Enfortumab Vedotin Versus Chemotherapy
Abstract In comparison to chemotherapy, enfortumab vedotin (EV) prolonged overall survival in patients with previously treated advanced urothelial carcinoma in EV-301. The objective of the present study was to assess patient experiences of EV versus chemotherapy using patient-reported outcome (PRO) analysis of health-related quality of life (HRQoL).
Health-related Quality of Life in Patients with Previously Treated Advanced Urothelial Carcinoma from EV-301: A Phase 3 Trial of Enfortumab Vedotin Versus Chemotherapy
Abstract In comparison to chemotherapy, enfortumab vedotin (EV) prolonged overall survival in patients with previously treated advanced urothelial carcinoma in EV-301. The objective of the present study was to assess patient experiences of EV versus chemotherapy using patient-reported outcome (PRO) analysis of health-related quality of life (HRQoL).
Comments - Finding Ilene - by Jonathan Rosenberg
Those of us who are not divorced may attribute that to many factors, including simply good luck rather than virtue. I have friends, good people all, who are divorced but never wanted to be. But Mr. Rosenberg's story is very sad for reasons other than luck, notwithstanding his current solid relationship.
Finding Ilene
While I have not lived past lives, I’ve had many past wives. And as it turns out, those do win you some wisdom. In my seventy-two years I’ve been married five times, once per decade beginning in my twenties. I’m not proud of this, but it does help define me. Some may call me naive, and I’m sure some of my ex-wives would call me worse. From those marriages came two children, two stepchildren, two grandchildren, and an all but empty bank account. And naturally, some lessons. My first wedding was in 1973.
NOXP: SEASON 1
Campaign Rewards FAQ Community NOXP is a webseries of animated shorts about five incredibly powerful heroes that have saved their world from destruction and completed their epic quest. Now, they must face something even scarier: Everyday life. Watch the first fifteen shorts here: If you don't already know me, my name is Gene! I've been working in animation for almost 20 years, starting with Hyperboy, a series of shorts I started when I was 14.
Enfortumab Vedotin and Pembrolizumab Combo Approved for Urothelial Carcinoma - Expert Insights and Impressive Response Rates - Jonathan E. Rosenberg
Alicia Morgans speaks with Jonathan Rosenberg about the approval of the combination of Enfortumab vedotin (EV) and Pembrolizumab for urothelial carcinoma treatment. Rosenberg notes the impressive response rates (64.5%) from the combination, as compared to EV monotherapy (45%), and highlights the promising survival rates, which significantly exceed expectations for a cisplatin-eligible population.
Shattering Expectations: The Success of Enfortumab Vedotin and Pembrolizumab in Urothelial Carcinoma - Jonathan E. Rosenberg
Alicia Morgans speaks with Jonathan Rosenberg about the recent approval of the combination of Enfortumab vedotin (EV) and Pembrolizumab for urothelial carcinoma treatment. Rosenberg notes the impressive response rates (64.5%) from the combination, as compared to EV monotherapy (45%), and highlights the promising survival rates, which significantly exceed expectations for a cisplatin-eligible population.
The Third Era of AI is Upon Us
It’s almost impossible to scroll through social media these days without seeing stories about OpenAI, GPT3, Large Language Models (LLM), ChatGPT and Bing’s chat assistant. This flood of news makes it seem like AI has only now just arrived.
Safety of Intravenous Administration of an AAV8 Vector Coding for an Oxidation-Resistant Human α1-Antitrypsin for the Treatment of α1-Antitrypsin Deficiency | Human Gene Therapy
Human Gene TherapyVol. 34, No. 3-4 Clinical DevelopmentsFree Access Abstract α1-antitrypsin (AAT) deficiency is a common autosomal recessive hereditary disorder, with a high risk for the development of early-onset panacinar emphysema. AAT, produced primarily in the liver, functions to protect the lung from neutrophil protease; with AAT deficiency, unimpeded neutrophil proteases destroy the lung parenchyma.
AI will Spearhead the Evolution of Contact Centers in 2023
Industry executives and experts share their predictions for 2023. Read them in this 15th annual VMblog.com series exclusive. By Jonathan Rosenberg, CTO and Head of AI, Five9 AI has always held the potential to significantly transform the contact center. Faster response times for customers and lower costs for businesses are just two of the many benefits it can bring. The reality is these benefits have only come to a small percentage of the contact centers worldwide.
Uncharted Reboot From New Developer Reportedly In The Works
Rumors suggest that an Uncharted reboot game is currently in the works, with series creator Naughty Dog stepping back to assist a new studio. An Uncharted reboot game is currently in the works, according to rumors, but not at previous developer Naughty Dog. The thrilling adventures of Nathan Drake seemingly came to an end with 2016's Uncharted 4: A Thief's End, though that game did hint at future adventures for other characters.
The 5 best leadership books I read this year — and what they taught me about running a company Original
David Siegel was hired by Adam Neumann to serve as the CEO of Meetup in 2018. For a roadmap for effective, kind leadership and smart decision-making, he shares 5 book recommendations. He describes his past mistakes like making unilateral decisions too early and worrying too much about being liked. I've been an avid reader of leadership and management books for over 30 years, but I never found a book that fully satisfied my interest in making better business and life decisions as a leader.
Long-Term Outcomes in EV-301, Enfortumab Vedotin Versus Chemotherapy in Patients With Previously Treated Advanced Urothelial Carcinoma - Jonathan Rosenberg
Read the Full Video Transcript Alicia Morgans: Hi, I'm so excited to be at ASCO 2022, where I have the opportunity to speak with Dr. Jonathan Rosenberg of Memorial Sloan Kettering. Thank you so much for talking with me. Jonathan Rosenberg: My pleasure. It's good to be here. Alicia Morgans: It's wonderful to talk to you and really exciting to hear about the updated results from EV-301, which you presented during the meeting.
EV-103 Cohort K, Enfortumab Vedotin Monotherapy or in Combination With Pembrolizumab in Previously Untreated Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer - Jonathan E. Rosenberg
Read the Full Video Transcript Alicia Morgans: Hi, I'm so excited to be at ESMO 2022 with Dr. Jonathan Rosenberg. Thank you so much for talking with me. Jonathan Rosenberg: My pleasure. It's good to be here today with you. Alicia Morgans: It is great to see you today. I'm so excited to talk about Cohort K and the results that were presented at ESMO. Can you share a little bit of those data? Jonathan Rosenberg: Sure.
Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU) | Journal of Clinical Oncology
Visual Abstract Visual Abstract Data Sharing Statement Data Sharing Statement Study Protocol The following protocol information is provided solely to describe how the authors conducted the research underlying this article. The information provided may not reflect the complete protocol or any previous amendments or modifications. As described in the , JCO requests only specific elements of the most recent version of the protocol.
Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU) | Journal of Clinical Oncology
Cisplatin-based chemotherapy remains the standard of care for the first-line treatment of patients with metastatic urothelial carcinoma (mUC), but approximately 40% of patients are unfit for these regimens because of renal impairment, poor performance status, or other comorbidities.1 Cisplatin-ineligible patients may receive carboplatin-based regimens, although median overall survival (OS) is longer with the former regimens.2 Patients ineligible for cisplatin-based chemotherapy are also...
Opinion: My play 'Americano' amplifies hope and optimism for the 3.6 million Dreamers in the U.S.
Rosenberg is a playwright and former educator and administrator involved with special needs children. His most recent musical, “Americano,” opened at the Phoenix Theatre in 2020, and is on an off-Broadway run at New World Stages in New York. He lives in Carmel Valley. When he was 18, Phoenix resident Tony Valdovinos went to enlist in the United States Marine Corps to fulfill a promise that he had made to himself on Sept. 11, 2001.
Council Post: Telco Mysteries Revealed: Why No One Is There When You Answer Unknown Callers
Pioneer in the telecommunications industry with over 25 years of experience. Jonathan is currently the CTO and Head of AI at Five9. We’ve all experienced it. Your phone rings—and it’s from an unknown number. It’s probably a robocall. You probably shouldn’t bother answering. But you’ve also been waiting for a callback from a contractor you need to talk to, and just maybe it’s them. So, you answer the call. “Hello?” No response. “Helllloooo??” Still no response.
20 Years of SIP - a Retrospective
The Phone Network Re-Engineered Prior to SIP, the telephone network was built using telephone switches based on custom hardware. These switches were made by a small set of vendors and were a completely verticalized solution from the physical networking layer to the application layer software. With the mainstream adoption of IP networks, it became possible to replace that hardware with general purpose computers running SIP based software applications.
Why Humanity Can Make A Vaccine In Less Than A Year But Can't Stop Robocalls
Pioneer in the telecommunications industry with over 25 years of experience. Jonathan is currently the CTO and Head of AI at . I've spent my entire career-25 years and counting-working in the telecommunications industry. This is a field that many people are familiar with as consumers, but most of them are completely unfamiliar with how it works.
The Effect of Durvalumab and Olaparib on Prolong Progression-Free Survival As First-Line Therapy in Platinum-Ineligible Patients With Unresectable Urothelial Carcinoma - The BAYOU Study - Jonathan Rosenberg
Read the Full Video Transcript Alicia Morgans: Hi, my name is Alicia Morgans, and I'm a GU medical oncologist at Dana-Farber Cancer Institute. I'm so excited to have here with me today, a friend and colleague, Dr. Jonathan Rosenberg, who is the chief of the GU medical oncology service, and a professor in medicine, at Memorial Sloan Kettering Cancer Center in New York City. Thank you so much for being here with me today, Jonathan. Jonathan Rosenberg: My absolute pleasure.
Op-Ed: A Putin supporter's Carnegie Hall appearance was canceled. Should art be separated from politics?
Conductor Valery Gergiev performs with the Mariinsky Theatre Symphony Orchestra at Zaryadye Concert Hall in Moscow on Jan. 22. (Sergei Fadeichev / TASS via Getty Images) Last weekend, the Vienna Philharmonic returned to New York for three performances, its first appearances in the United States since 2019.
ASCO GU 2022: Management of Rare Variants in Genitourinary Cancers: Systemic Therapy for Rare Variants of Urothelial Cancer
(UroToday.com) The 2022 GU ASCO Annual meeting included a session on the management of rare variants in genitourinary cancers and a presentation by Dr. Jonathan Rosenberg discussing the role of systemic therapy for the management of rare variant histology in urothelial cancer. Dr. Rosenberg notes that the optimal systemic therapy of variant histology in bladder cancer has not been defined.
The Top 5 AI Pitfalls in the Contact Center and How to Avoid Them
Organizations across industries are leveraging artificial intelligence to both improve customer and agent experience and reduce labor costs. Today, AI is becoming embedded into business processes and driving the growth in enterprise automation, helping teams deliver speed, quality, and resilience. I'm excited about what AI is doing for the contact center. Yet, it's important to remember that how you deploy AI to meet your needs is not just about the technology.
Sacituzumab Govitecan-hziy: Welcome Addition to Advanced Urothelial Cancer Treatments, but Time to Figure Out Sequencing and Combinations
By Brendan J. Guercio, MD, and Jonathan E. Rosenberg, MD July 10, 2021 Advertisement Jonathan E.
Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance) | Journal of Clinical Oncology
Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance) The following represents disclosure information provided by the authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript.
The Treatment Landscape for Advanced Urothelial Carcinoma in 2021 - Jonathan Rosenberg
Read the Full Video Transcript Alicia Morgans: Hi, my name is Alicia Morgans. I'm a GU medical oncologist and associate professor of medicine at Northwestern University. I'm so excited to have here with me today, a good friend and colleague, Dr. Jonathan Rosenberg, who is a professor of medicine and the chief of the GU Medical Oncology Service at Memorial Sloan Kettering in New York. Thank you so much for being here with me today, Jonathan. Jonathan Rosenberg: An absolute pleasure.
New Treatments for Patients With Progressive Metastatic Urothelial Carcinoma
H&O Does urothelial carcinoma pose any challenges or opportunities for the development of new drugs? JRUrothelial carcinoma tends to affect older patients, who often have comorbidities that complicate treatment. The average age of patients with urothelial cancer at diagnosis is 73 years. Among these older patients, organ function may not be adequate for certain therapies, particularly cisplatin.
Advice From Google On How The Board Can Help With Digital Transformation
Over the past couple of years, the profit gap between top and bottom performing companies has grown significantly. A McKinsey study finds that since 2018 the top quintile of performers grew their “market implied economic profit,” a metric based on profit, market cap and capital investment, by $353 billion, while bottom quintile performers saw the same metric drop by $303B. The trend applies across virtually every sector.
Quantitative Whole-Body Imaging of I-124-Labeled Adeno-Associated Viral Vector Biodistribution in Nonhuman Primates
Introduction Recombinant adeno-associated virus (AAV) vectors are small, single-stranded DNA parvoviruses, in which the viral genes are replaced by an expression cassette containing a transgene of therapeutic interest.1–3 AAV vectors are widely used for in vivo gene delivery,1–6 have minimal pathogenicity, and mediate persistent expression for the life of nonproliferating cells.1–3,6–12 The target organ(s), capsid structure, route of administration, and preexisting immunity can each modify...
The biology and rationale of targeting nectin-4 in urothelial carcinoma
1. Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394–424 (2018). PubMed PubMed Central Article Google Scholar 2. Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2020. CA Cancer J. Clin. 70, 7–30 (2020). PubMed Article PubMed Central Google Scholar 3. Cancer.Net Editorial Board. Bladder cancer: statistics. Cancer.Net https://www.cancer.net/cancer-types/bladder-cancer/statistics (2020). 4.
Re: Russell E.N. Becker, Alexa R. Meyer, Aaron Brant, et al. Clinical Restaging and Tumor Sequencing are Inaccurate Indicators of Response to Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo
Radical cystectomy with pelvic node dissection (RC) remains a gold standard for the management of muscle-invasive bladder cancer (MIBC), frequently resulting in excellent long-term disease control. Significant improvements in survival have been achieved with the addition of neoadjuvant chemotherapy (NAC), while four decades of advances in neobladder reconstruction have led to enhanced quality of life for many patients.
What would Bill Campbell do?
By Eric Schmidt and Jonathan Rosenberg and Alan Eagle10 minute Read Since the onset of the COVID-19 pandemic and protests against racial injustice, we are often asked, “What would Bill do?” The Bill in question is Bill Campbell, our late friend and coach, and the subject of Trillion Dollar Coach, the book we published about him last year.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Jonathan
Contact Jonathan, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack